297 related articles for article (PubMed ID: 36834806)
41. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
[TBL] [Abstract][Full Text] [Related]
42. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
43. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
45. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
46. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
47. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
[TBL] [Abstract][Full Text] [Related]
48. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
[TBL] [Abstract][Full Text] [Related]
49. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
[TBL] [Abstract][Full Text] [Related]
50. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
51. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
Kato JY; Korenaga S; Iwakura M
Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
[TBL] [Abstract][Full Text] [Related]
52. Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults.
Dos Santos RS; Guzman-Llorens D; Perez-Serna AA; Nadal A; Marroqui L
Front Immunol; 2023; 14():1263926. PubMed ID: 37854597
[TBL] [Abstract][Full Text] [Related]
53. Design of a peptide inhibitor of tyrosine kinase 2.
Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
[TBL] [Abstract][Full Text] [Related]
54. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S
J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213
[TBL] [Abstract][Full Text] [Related]
55. Deucravacitinib in moderate-to-severe psoriasis.
Vu A; Maloney V; Gordon KB
Immunotherapy; 2022 Nov; 14(16):1279-1290. PubMed ID: 36373503
[TBL] [Abstract][Full Text] [Related]
56. From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.
Hromadová D; Elewaut D; Inman RD; Strobl B; Gracey E
Front Genet; 2021; 12():685280. PubMed ID: 34290741
[TBL] [Abstract][Full Text] [Related]
57. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
[TBL] [Abstract][Full Text] [Related]
58. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract][Full Text] [Related]
59. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
[TBL] [Abstract][Full Text] [Related]
60. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.
Strobl B; Stoiber D; Sexl V; Mueller M
Front Biosci (Landmark Ed); 2011 Jun; 16(9):3214-32. PubMed ID: 21622231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]